Drugs Health Pharma

Novartis to pay Monte Rosa $150m upfront for MGD drug candidates

Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise.

Read More